EP0794193A1 - Substance mk7634, process for production thereof, and anthelminthic containing said substance - Google Patents
Substance mk7634, process for production thereof, and anthelminthic containing said substance Download PDFInfo
- Publication number
- EP0794193A1 EP0794193A1 EP95937171A EP95937171A EP0794193A1 EP 0794193 A1 EP0794193 A1 EP 0794193A1 EP 95937171 A EP95937171 A EP 95937171A EP 95937171 A EP95937171 A EP 95937171A EP 0794193 A1 EP0794193 A1 EP 0794193A1
- Authority
- EP
- European Patent Office
- Prior art keywords
- substance
- culture
- water
- producing
- fractions
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/14—Fungi; Culture media therefor
- C12N1/145—Fungal isolates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P1/00—Preparation of compounds or compositions, not provided for in groups C12P3/00 - C12P39/00, by using microorganisms or enzymes
- C12P1/02—Preparation of compounds or compositions, not provided for in groups C12P3/00 - C12P39/00, by using microorganisms or enzymes by using fungi
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/645—Fungi ; Processes using fungi
Definitions
- the present invention relates to MK7634 substance having anthelmintic activity, process for production thereof and use thereof as an anthelmintic containing it.
- Illnesses called parasitic diseases generally caused by parasites living on hosts and give serious damages to human and animal health and agriculture.
- the present inventors provide a novel compound having anthelmintic activity, establish advantageous process for producing it and provide an anthelmintic containing the compound, thereby satisfying the above demand.
- the present inventors continued a search of a substance having anthelmintic activity and found that a substance having anthelmintic activity is produced in a culture of a strain belonging to imperfect fungi.
- the present inventors isolated the active ingredient and determined physicochemical properties thereof and thus completed the present invention.
- the present invention relates to a substance exhibiting the following physicochemical properties (referred to as MK7634 substance hereinafter), a process for producing it and a drug, in particular an anthelmintic, containing the MK7634 substance as an active ingredient.
- Fig. 1 shows UV spectrum of the MK7634 substance in an aqueous solution .
- Fig. 2 shows IR spectrum of the MK7634 substance by the KBr method.
- the MK7634 substance of the present invention can be obtained by, for example, culturing a microorganism belonging to imperfect fungi and capable of producing the MK7634 substance and collecting the MK7634 substance from its culture.
- a microorganism though it is not limited to specific ones so long as it has the property mentioned above, a fungus producing the substance and belonging to the genus Curvularia is preferably mentioned. More specifically, Curvularla pallescens D2479 (sometimes referred to simply "the strain” or abbreviated as "D2479” hereinafter), which has been isolated by the present inventors from dead plant bodies, can be mentioned as a preferred fungus producing the substance.
- Mycological characteristics of the strain are as follows. This strain was deposited at the Agency of Industrial Science and Technology, the National Institute of Bioscience and Human-technology (NIBH, Postal code: 305, 1-1-3 Higashi, Tsukuba-shi, Ibaraki-ken, Japan) on November 17, 1994 and received an accession number of FERM P-14645, and transferred to international deposition under the Budapest Treaty on October 30, 1995 and received an accession number of FERM BP-5276 .
- the strain actively forms cotton pile-like colonies in culture at 27°C for 2 weeks on a potato dextrose agar culture medium [PDA: a culture medium containing 4.0 g of potato extract powder, 20.0 g of glucose and 15.0 g of agar (NISSUI Pharmaceutical) in 1 liter of water (pH 6.0 ⁇ 0.1), NISSUI Pharmaceutical Co., Ltd., Product Summary I, p92], and the colonies present light brown gray color earlier and dark brown later.
- PDA potato dextrose agar culture medium
- NISSUI Pharmaceutical a culture medium containing 4.0 g of potato extract powder, 20.0 g of glucose and 15.0 g of agar (NISSUI Pharmaceutical) in 1 liter of water (pH 6.0 ⁇ 0.1), NISSUI Pharmaceutical Co., Ltd., Product Summary I, p92]
- Basal hyphae branch have many partitions and a width of 3.0 to 16 mm and present pale brown to dark brown color.
- Chlamydospores are not formed.
- Conidiophores are mononematous, show acrogenesis and pleurogenesis on vegetative hyphae, normally do not branch, but branch sometimes, stand straight or curve, often show zigzag shape at upper portions, present pale brown to dark reddish-brown color, have several partitions, a length of 70 to 450 mm, a width of 3.8 to 5.0 mm, are thin at stems, and swell toward ends.
- Conidia show fusiform or fusiform rod shape and have 3 partitions, the third cell from the bottom swells, the third cell curves in a comma shape or does not curve, and each cell of conidia presents uniform pale brown, is smooth, and has a size of 17.8 to 31.2 x 5.3 to 12.0 mm, and conidia have no projecting hilum at their basal parts.
- Basal hyphae branch have many partitions and a width of 2.2 to 10 mm and present pale to pale brown color.
- Chlamydospores are not formed.
- Conidia form abundantly particularly in peripheries of colonies and characteristics of anamorphs of conidiophores and conidia are similar to those observed on PDA culture medium.
- This strain belongs to the genus Curvularia , a group forming poloconidia of the class imperfect filamnetous fungus of the subdivision imperfect fungus, because it is characterized in that 1) it shows poloconidia formation, 2) conidiophores are straight or curved, or often zigzag and conidia form acropetally and 3) conidia have 3 partitions, swelled intermediate cells are always present and some conidia curve in a comma shape.
- This genus is distinguished from an analogous genus Drechslera because of the characteristics of conidia, i.e., they have true partitions, have 3 to 4 partitions and have swelled intermediate cells..
- Curvularia lunata and Curvularia leonensis are mentioned as analogous species, but Curvularia pallescens is distinguished from these species by the characteristics shown in Table 1.
- Table 1 Characteristics of conidia D2479 C. pallescens C. leonensis C.
- Characteristics of this strain are likely to change like other fungi. For example, any mutants (naturally occurred or induced), phenotypic zygotes and genetic recombinants of this strain or derived from this strain can be used for the present invention so long as they produce the MK7634 substance.
- a fungus producing the MK7634 substance and belonging to imperfect filamentous fungi is cultured in a culture medium containing nutrients which can be utilized by usual microorganisms.
- nutrients those known for use in conventional culture of fungi can be used.
- a carbon source rice, glucose, starch syrup, dextrin, starch, molasses, animal and vegetable oils and the like can be used.
- a nitrogen source soybean meal, wheat germ, corn steep liquor, cotton seed meal, meat extract, peptone, yeast extract, ammonium sulfate, sodium nitrate, urea and the like can be used.
- an inorganic salt capable of producing ions such as sodium, potassium, calcium, magnesium, cobalt, chlorine, phosphate and sulfate ions as required. It is also possible to add any organic or inorganic substance enhancing growth of the fungi and production of the MK7634 substance.
- a preferred temperature for the cultivation is within 15 to 35°C, but more preferably it is cultured at a temperature around 20 to 30°C.
- accumulation of the substance usually reaches maximum within 2-14 days in any of solid culture, shaking culture and tank culture.
- the MK7634 substance obtained by the present invention can be collected and purified from a culture of MK7634 substance producing fungi by a separation means utilizing the properties of the substance, for example, solvent extraction, ion exchange resin technique, adsorption or distribution column chromatography, gel filtration, dialysis, precipitation and any combination thereof.
- the MK7634 substance is extracted from cultured fungi with acetone/water, methanol/water or the like. After evaporating acetone or methanol contained in the extract, the aqueous layer is washed successively with ethyl acetate, n-butanol or the like.
- the active ingredient can be eluted with aqueous ammonia or the like.
- an ion exchange resin for example, Diaion PK-208 (H+), Mitsubishi Chemical Corporation, Diaion is a registered trademark
- the MK7634 substance can be purified by subjecting a sample obtained by neutralization and lyophilization to gel filtration chromatography utilizing a molecular sieve resin (trade name; Sephadex G-10, Pharmacia) and then gel filtration chromatography utilizing another molecular sieve resin (Toyopearl HW-40S, Tosoh, or the like).
- the MK7634 substance can be utilized as an active ingredient of pharmaceutical drugs, in particular, anthelmintics.
- anthelmintics examples include human and domestic animals, domestic fowls, experimental animals and pet animals such as pig, cow, horse, rabbit, sheep, goat, chicken, duck, turkey, house mouse, albino rat, guinea pig, monkey, dog, cat and birdie.
- Examples of parasites of these animals include Haemonchus worm, Ostertagia parasitem, hairworm, Cooper nematode, oesophagostomum, strongyloides, aphistome, Benedeen cestode, lungworm, liver hirudinea and the like of cow and sheep, roundworm, whipworm, oesophagostomum of pig, roundworm, hookworm, whipworm, Filarioidea and the like of dog, roundworm, Diphyllobothrium erinacei and the like of cat, roundworm, hairworm, caecum nematode and the like of chicken.
- Human roundworm, Enterobius, hookworms (Ancylostoma duodenale, Ancylostoma ceylanicum, American hookworm), oriental trichostrongylus, strongyloides, whipworm and the like are also included.
- the MK7634 substance can be used for treatment and prevention of various diseases, in particular, treatment and prevention of parasitic infections.
- Administration for treatment can be done orally or parenterally.
- the substance can be obligatorily administered through a gastric catheter or the like as a liquid drug, or administered by mixing it in usual feed or drinking water, or administered in a usual form suitable for oral administration, for example, tablets, capsules, pellets, boluses, powders and soft capsules.
- the substance is normally administered orally by mixing it in usual feed and the like, or administered by injection.
- administration period is not particularly limited and, for example, about 2 months for meat chickens and 5 months for pigs are often sufficient.
- Administration dose of the MK7634 substance varies depending on kinds of objective animals and parasites or administration method. For example, 3 mg/kg or more, preferably 6 mg/kg or more is administered when the substance is orally administered as a liquid drug through a gastric catheter in order to get rid of roundworms of chickens. For the prevention, the substance is continuously administered at a concentration of 1 ppm or more, preferably 5 to 10 ppm in feed.
- the MK7634 substance By dissolving or suspending the MK7634 substance in a liquid carrier, it can be administered parenterally by subcutaneous or intramuscular injection or the like to animals.
- a water-insoluble formulation containing peanut oil, soy bean oil or the like as well as a water-soluble formulation containing glycerol, polyethylene glycol or the like can be used.
- These formulations generally contains the MK7634 substance at a concentration of 0.1 to 10% by weight.
- Daily administration dose for parenteral administration is 0.5 mg/kg or more, preferably 1 to 20 mg/kg.
- Chickens orally administered with the MK7684 substance show normal weight gain and other anomalies are not recognized. This indicates extremely low toxicity of the substance.
- each of rice and 20 ml each of tap water were introduced into 60 of 500-ml Erlenmeyer flasks and sterilized by autoclaving at 121°C for 20 minutes.
- 4 ml each of the above seed culture medium was inoculated and cultured by leaving them stand at 27°C for 14 days.
- This 145 mg of active fraction was combined with the previously obtained 124 mg of active fraction dissolved in 10 ml of purified water, adjusted to pH 7.3, subjected to column chromatography using a column charged with 480 ml of a molecular sieving resin (Sephadex G-10, Pharmacia) and purified water and fractionated into 2 ml fractions. Fractions No. 49 to No. 55 were collected to afford 84 mg of an active fraction.
- a molecular sieving resin Sephadex G-10, Pharmacia
- This 203 mg of active fraction was dissolved in 10 ml of purified water, adjusted to pH 7.3, subjected to column chromatography using a column charged with 600 ml of a molecular sieving resin (Sephadex G-10, Pharmacia) and purified water and fractionated into 2 ml fractions.
- Fractions No. 37 to No. 47 were collected to afford 74.7 mg of an active fraction.
- This 74.7 mg of active fraction was dissolved in 6 ml of purified water, adjusted to pH 7.3, subjected to column chromatography using a column charged with 340 ml of a molecular sieving resin (TOYOPEARL HW-40S, Tosoh) and purified water and fractionated into 2 ml fractions.
- Fractions No. 56 to No. 67 were collected and lyophilized to afford 4.0 mg of the MK7634 substance as colorless powder.
- Physicochemical characteristics of the MK7634 substance corresponded to those described above.
- the molecular weight and the molecular formula were obtained by determining high resolution mass spectrum of a monodansylated compound of the substance, which was obtained by dansylating the substance.
- the MK7634 substance was orally administered at one time by a feeding tube as a gelatin capsule containing a dose accurately calculated based on body weight of each chicken. After administration, number of discharged roundworms was counted for each chicken every day and, 7 days later, each chicken was dissected to count the residual number of the worm in the bowel and calculate the worm discharging ratio.
- Worm discharging ratio [Number of discharged worms in 7 days/(Number of discharged worms in 7 days + Number of residual worms in bowel)] x 100
- Body weight of each chicken was measured immediately before the administration and 7 days after the administration and body weight increasing ratio was calculated.
- Body weight increasing ratio [(Body weight 7 days after administration - Body weight upon administration)/Body weight upon administration] x 100
- the results of the above examination are shown in Table 2.
- the MK7634 substance showed a worm discharging ratio of 97.4 % at 6.06 mg/kg.
- the body weight increasing ratio was almost equal to that of no medication control even when this substance was administered at 31.9 mg/kg and hence it was confirmed that the MK7634 substance was a relatively safe drug.
- Table 2 Chicken roundworm discharging test by MK7634 substance administration Chicken No. Administration dose (mg/kg) Worm discharging ratio (%) Body weigh increasing ratio (%) 1 No medication 0 18.0 2 2.89 61.3 49.3 3 6.06 97.4 16.4 4 15.3 100 23.4 5 31.9 100 25.0
- the MK7634 substance of the present invention is expected to be used as an anthelmintic against parasites in humans and/or domestic animals and fowls and the like.
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Mycology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Botany (AREA)
- General Chemical & Material Sciences (AREA)
- Tropical Medicine & Parasitology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Medical Informatics (AREA)
- Epidemiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Virology (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Compounds Of Unknown Constitution (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Feed For Specific Animals (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
- The present invention relates to MK7634 substance having anthelmintic activity, process for production thereof and use thereof as an anthelmintic containing it.
- Illnesses called parasitic diseases generally caused by parasites living on hosts and give serious damages to human and animal health and agriculture.
- In order to treat or prevent such parasitic diseases, various drugs have hitherto been searched for. For example, as anthelmintically active substances derived from microorganisms, destomycin, hygromycin, abelmectin and the like have been reported. However, number of such substances is very small. Accordingly, appearance of novel anthelmintically active substance is always demanded.
- The present inventors provide a novel compound having anthelmintic activity, establish advantageous process for producing it and provide an anthelmintic containing the compound, thereby satisfying the above demand.
- To satisfy the above demand, the present inventors continued a search of a substance having anthelmintic activity and found that a substance having anthelmintic activity is produced in a culture of a strain belonging to imperfect fungi. The present inventors isolated the active ingredient and determined physicochemical properties thereof and thus completed the present invention.
- Therefore, the present invention relates to a substance exhibiting the following physicochemical properties (referred to as MK7634 substance hereinafter), a process for producing it and a drug, in particular an anthelmintic, containing the MK7634 substance as an active ingredient.
- (1) Color and form: colorless powder
- (2) Molecular formula: C8H15N3O4
- (3) Specific rotation: [α]D25= +32.8° (c = 0.5, H2O)
- (4) Mass spectrum (SI-MS): m/z 240 (MNa)+, 218 (MH)+
- (5) Ultra-violet absorption spectrum: λmax (H2O) nm = 193(end absorption)
- (6) Infra-red absorption spectrum: νmax (KBr)cm-1 = 3400, 1670, 1630, 1405, 1350, 1090, 970
- (7) Melting point: gradually colored and decomposed from 175°C
- (8) Solubility: soluble in water and insoluble in ether, chloroform and ethylacetate
- (9) basicity, acidity and neutrality: basic
- (10) Color reaction: positive in ninhydrin, GL and molybdic acid reactions
- (11) Thin layer chromatography: Rf value is 0.3 (developing solvent is a mixed solvent of n-butanol, ethanol, chloroform and 17% ammonia (weight mixing ratio = 4:5:2:5).
- Fig. 1 shows UV spectrum of the MK7634 substance in an aqueous solution .
- Fig. 2 shows IR spectrum of the MK7634 substance by the KBr method.
- Fig. 3 shows 1H-NMR spectrum (400 MHz) of monodansylated MK7634 substance in a mixed solution of deuterium oxide and deuterated methanol (mixing weight ratio =4:1).
- Fig.4 shows 13C-NMR spectrum (100 MHz) of monodansylated MK7634 substance in a mixed solution of deuterium oxide and deuterated methanol (mixing weight ratio =4:1).
- The present invention will be explained in detail hereinafter.
- The MK7634 substance of the present invention can be obtained by, for example, culturing a microorganism belonging to imperfect fungi and capable of producing the MK7634 substance and collecting the MK7634 substance from its culture. As such a microorganism, though it is not limited to specific ones so long as it has the property mentioned above, a fungus producing the substance and belonging to the genus Curvularia is preferably mentioned. More specifically, Curvularla pallescens D2479 (sometimes referred to simply "the strain" or abbreviated as "D2479" hereinafter), which has been isolated by the present inventors from dead plant bodies, can be mentioned as a preferred fungus producing the substance.
- Mycological characteristics of the strain are as follows. This strain was deposited at the Agency of Industrial Science and Technology, the National Institute of Bioscience and Human-technology (NIBH, Postal code: 305, 1-1-3 Higashi, Tsukuba-shi, Ibaraki-ken, Japan) on November 17, 1994 and received an accession number of FERM P-14645, and transferred to international deposition under the Budapest Treaty on October 30, 1995 and received an accession number of FERM BP-5276 .
- As to colony formation, the strain actively forms cotton pile-like colonies in culture at 27°C for 2 weeks on a potato dextrose agar culture medium [PDA: a culture medium containing 4.0 g of potato extract powder, 20.0 g of glucose and 15.0 g of agar (NISSUI Pharmaceutical) in 1 liter of water (pH 6.0 ± 0.1), NISSUI Pharmaceutical Co., Ltd., Product Summary I, p92], and the colonies present light brown gray color earlier and dark brown later.
- Basal hyphae branch, have many partitions and a width of 3.0 to 16 mm and present pale brown to dark brown color.
- Chlamydospores are not formed.
- Development of aerial hyphae is abundant.
- Conidiophores are mononematous, show acrogenesis and pleurogenesis on vegetative hyphae, normally do not branch, but branch sometimes, stand straight or curve, often show zigzag shape at upper portions, present pale brown to dark reddish-brown color, have several partitions, a length of 70 to 450 mm, a width of 3.8 to 5.0 mm, are thin at stems, and swell toward ends.
- Poloconidia are formed, and secession marks (scars) are indistinct.
- Conidia show fusiform or fusiform rod shape and have 3 partitions, the third cell from the bottom swells, the third cell curves in a comma shape or does not curve, and each cell of conidia presents uniform pale brown, is smooth, and has a size of 17.8 to 31.2 x 5.3 to 12.0 mm, and conidia have no projecting hilum at their basal parts.
-
- ① The strain actively forms colonies in culture at 27°C for 2 weeks on a malt extract agar culture medium [MA (malt extract agar): a culture medium containing 20.0 g of malt extract, 1.0 g of peptone, 20.0 g of glucose and 20.0 g of agar in 1 liter of water (pH unmodified), Toshikazu Udagawa, Keisuke Tsubaki et al, Illustrated Book of Fungi, Vol. 2, Kodansha, p1281], and colonies present cotton pile-like to velvet-like shape and light brown gray color earlier and grayish black later.
Basal hyphae branch, have many partitions and reach a width of 14.7 mm and present pale brown to reddish brown color.
Chlamydospores are not formed.
Development of aerial hyphae is abundant.
Conidia form abundantly and characteristics of anamorphs of conidiophores and conidia are similar to those observed on PDA culture medium. - ② The strain moderately forms colonies in culture at 27°C for 2 weeks on Miura medium [LCA: a culture medium containing 1.0 g of glucose, 1.0 g of KH2PO4, 0.2 g of MgSO4·7H2O, 0.2 g of KCl, 2.0 g of NaNO3, 0.2 g of yeast extract and 15.0 g of agar in 1 liter of water (pH 6.5-7 .0), the Illustrated Book of Fungus, Vol. 2, supra, p1277], and colonies spread flatly and present cotton pile-like shape and brown gray color earlier and grayish yellow brown color later.
- Basal hyphae branch, have many partitions and a width of 2.2 to 10 mm and present pale to pale brown color.
- Chlamydospores are not formed.
- Development of aerial hyphae is abundant.
- Conidia form abundantly particularly in peripheries of colonies and characteristics of anamorphs of conidiophores and conidia are similar to those observed on PDA culture medium.
-
- Growth temperature (on PDA, 5-day culture): 15 to 35°C
- Optimal temperature: 25 to 30°C
- Growth pH (Miura medium, 7-day culture): 3 to 9
- Optimal pH: 5 to 7
- This strain (D2479) belongs to the genus Curvularia, a group forming poloconidia of the class imperfect filamnetous fungus of the subdivision imperfect fungus, because it is characterized in that 1) it shows poloconidia formation, 2) conidiophores are straight or curved, or often zigzag and conidia form acropetally and 3) conidia have 3 partitions, swelled intermediate cells are always present and some conidia curve in a comma shape. This genus is distinguished from an analogous genus Drechslera because of the characteristics of conidia, i.e., they have true partitions, have 3 to 4 partitions and have swelled intermediate cells..
- In the genus Curvularia, 40 or more species have been known. According to Dematiaceous Hyphomycetes, M. B. Ellis (1971), these 40 species are distinguished by difference of host plant and configuration of conidia (presence of hilum of conidium base parts, number of partitions and size, form, presence of inflection of conidia etc.). According to a search list of the species mentioned in Dematiaceous Hyphomycetes, M. B. Ellis, p.452-459 (1971), search of this strain (D2479) at species level was conducted. As a result, the characteristics of the strain well conformed to those of Curvularia pallescens and therefore the strain (D2479) was identified as Curvularia pallescens. Curvularia lunata and Curvularia leonensis are mentioned as analogous species, but Curvularia pallescens is distinguished from these species by the characteristics shown in Table 1.
Table 1 Characteristics of conidia D2479 C. pallescens C. leonensis C. lunata Number of Partition 3 Partitions 3 3 3 Swelled cells The third cell 3 3 3 Curved/straight Curved or straight Curved or straight Curved (knee or hook like shape) Curved Color All cells are uniformly pale brown All cells are uniformly pale brown All cells are uniformly pale brown Intermediate cells are dark brown; both polar cells are colorless to pale brown Size 17.8-31.2 x 5.3-12.0 mm 17-32 x 7-12 mm 20-32 x 9-13 mm 20-32 x 9-15 mm - Characteristics of this strain are likely to change like other fungi. For example, any mutants (naturally occurred or induced), phenotypic zygotes and genetic recombinants of this strain or derived from this strain can be used for the present invention so long as they produce the MK7634 substance.
- A fungus producing the MK7634 substance and belonging to imperfect filamentous fungi is cultured in a culture medium containing nutrients which can be utilized by usual microorganisms. As nutrients, those known for use in conventional culture of fungi can be used. For example, as a carbon source, rice, glucose, starch syrup, dextrin, starch, molasses, animal and vegetable oils and the like can be used. As a nitrogen source, soybean meal, wheat germ, corn steep liquor, cotton seed meal, meat extract, peptone, yeast extract, ammonium sulfate, sodium nitrate, urea and the like can be used. It is also effective to add an inorganic salt capable of producing ions such as sodium, potassium, calcium, magnesium, cobalt, chlorine, phosphate and sulfate ions as required. It is also possible to add any organic or inorganic substance enhancing growth of the fungi and production of the MK7634 substance.
- As culturing method, aerobic cultivation, in particular, solid culture methods and submerged culture methods are preferred. A preferred temperature for the cultivation is within 15 to 35°C, but more preferably it is cultured at a temperature around 20 to 30°C. Though the production of the MK7634 substance differently proceeds depending on the culture medium and culture conditions, accumulation of the substance usually reaches maximum within 2-14 days in any of solid culture, shaking culture and tank culture. When the quantity of accumulated MK7684 substance in culture becomes maximum, the cultivation is stopped and the target substance is isolated and purified from the culture medium.
- The MK7634 substance obtained by the present invention can be collected and purified from a culture of MK7634 substance producing fungi by a separation means utilizing the properties of the substance, for example, solvent extraction, ion exchange resin technique, adsorption or distribution column chromatography, gel filtration, dialysis, precipitation and any combination thereof. For example, the MK7634 substance is extracted from cultured fungi with acetone/water, methanol/water or the like. After evaporating acetone or methanol contained in the extract, the aqueous layer is washed successively with ethyl acetate, n-butanol or the like. By adjusting pH of the aqueous layer around neutral and adsorbing the substance with an ion exchange resin (for example, Diaion PK-208 (H+), Mitsubishi Chemical Corporation, Diaion is a registered trademark), the active ingredient can be eluted with aqueous ammonia or the like. The MK7634 substance can be purified by subjecting a sample obtained by neutralization and lyophilization to gel filtration chromatography utilizing a molecular sieve resin (trade name; Sephadex G-10, Pharmacia) and then gel filtration chromatography utilizing another molecular sieve resin (Toyopearl HW-40S, Tosoh, or the like).
- The MK7634 substance can be utilized as an active ingredient of pharmaceutical drugs, in particular, anthelmintics. Examples of creatures that can be administered with the MK7634 substance as an anthelmintic include human and domestic animals, domestic fowls, experimental animals and pet animals such as pig, cow, horse, rabbit, sheep, goat, chicken, duck, turkey, house mouse, albino rat, guinea pig, monkey, dog, cat and birdie. Examples of parasites of these animals include Haemonchus worm, Ostertagia parasitem, hairworm, Cooper nematode, oesophagostomum, strongyloides, aphistome, Benedeen cestode, lungworm, liver hirudinea and the like of cow and sheep, roundworm, whipworm, oesophagostomum of pig, roundworm, hookworm, whipworm, Filarioidea and the like of dog, roundworm, Diphyllobothrium erinacei and the like of cat, roundworm, hairworm, caecum nematode and the like of chicken. Human roundworm, Enterobius, hookworms (Ancylostoma duodenale, Ancylostoma ceylanicum, American hookworm), oriental trichostrongylus, strongyloides, whipworm and the like are also included.
- The MK7634 substance can be used for treatment and prevention of various diseases, in particular, treatment and prevention of parasitic infections. Administration for treatment can be done orally or parenterally. When it is orally administered, for example, the substance can be obligatorily administered through a gastric catheter or the like as a liquid drug, or administered by mixing it in usual feed or drinking water, or administered in a usual form suitable for oral administration, for example, tablets, capsules, pellets, boluses, powders and soft capsules. When it is administered parenterally, it can be administered percutaneously, subcutaneously, intramuscularly, intravenously, intraperitoneally or the like as a water-insoluble formulation containing peanut oil, soybean oil or the like or a water-soluble formulation containing glycerol, polyethylene glycol by injection or the like. For the prevention of parasitic infections, the substance is normally administered orally by mixing it in usual feed and the like, or administered by injection. For the prevention of parasitic infections, administration period is not particularly limited and, for example, about 2 months for meat chickens and 5 months for pigs are often sufficient.
- Administration dose of the MK7634 substance varies depending on kinds of objective animals and parasites or administration method. For example, 3 mg/kg or more, preferably 6 mg/kg or more is administered when the substance is orally administered as a liquid drug through a gastric catheter in order to get rid of roundworms of chickens. For the prevention, the substance is continuously administered at a concentration of 1 ppm or more, preferably 5 to 10 ppm in feed.
- By dissolving or suspending the MK7634 substance in a liquid carrier, it can be administered parenterally by subcutaneous or intramuscular injection or the like to animals. For the parenteral administration, a water-insoluble formulation containing peanut oil, soy bean oil or the like as well as a water-soluble formulation containing glycerol, polyethylene glycol or the like can be used. These formulations generally contains the MK7634 substance at a concentration of 0.1 to 10% by weight. Daily administration dose for parenteral administration is 0.5 mg/kg or more, preferably 1 to 20 mg/kg.
- Chickens orally administered with the MK7684 substance show normal weight gain and other anomalies are not recognized. This indicates extremely low toxicity of the substance.
- Working examples of the present invention will be described hereinafter. Because the characteristics of the MK7634 substance are clarified by the present invention, various methods for producing MK7634 substance can be established based on the characteristics. Therefore, the present invention is not limited to the following examples and not only any modifications of the examples but also any methods for production, concentration, extraction and purification of MK7684 substance elaborated based on the characteristics of the MK7634 substance revealed by the present invention and utilizing conventional means will fall within the scope of the present invention.
- 40 ml each of a culture medium containing 2.0% of starch syrup, 1.0% of soybean meal, 0.15% of soybean oil, 0.25 % of Sungrain (Suntory), 0.15% of cotton seed meal, 0 .0005% of FeSO4·7H2O, 0.00005% of NiCl2·6H2O, 0.00005% of CoCl2·6H2O and 0.1% of CaCO3 (pH6.0) was charged in 120 of 200-ml Erlenmeyer flasks and sterilized by autoclaving at 121°C for 20 minutes. The strain was inoculated to each of these flasks in an amount of one platinum loop and cultured by shaking at 27°C for 2 days at 210 revolutions per minute.
- Separately, 60 g each of rice and 20 ml each of tap water were introduced into 60 of 500-ml Erlenmeyer flasks and sterilized by autoclaving at 121°C for 20 minutes. To these main culture media, 4 ml each of the above seed culture medium was inoculated and cultured by leaving them stand at 27°C for 14 days.
- 90 liters of 50% aqueous acetone was added to the obtained solid culture containing fungi, stirred for 1 hour and isolated the fungi by filtration to afford an extract. The fungi taken by filtration was stirred with the same amount of water for 1 hour and the fungi were separated by filtration to afford an aqueous extract. The above aqueous acetone and the aqueous extract were combined and concentrated under reduced pressure and then the acetone was evaporated to obtain 50.1 liters of an extract. Subsequently, this extract was added with 50 liters of ethyl acetate and washed for one hour by stirring. 50 liters of the aqueous layer was concentrated to 18 liters under reduced pressure, added with the same amount of n-butanol and washed for one hour by stirring. 18 liters of this aqueous layer was concentrated to 13.8 liters under reduced pressure and pH was adjusted to 7.0. This concentrate was adsorbed on a column charged with 2 liters of an ion exchange resin (Diaion PK-208(H+), Mitsubishi Chemical Corporation). The active ingredient was afforded from fractions eluted with 0.5N aqueous ammonia. After adjusting pH to 7.0, 450 ml of this eluate was again adsorbed on a column charged with 1 liter of an ion exchange resin (Diaion PK-208(H+), Mitsubishi Chemical Corporation) and chromatographed with a concentration gradient formed by 1 liter of purified water and 1 liter of 0.5N aqueous ammonia, and 15 ml fractions were collected. 8.5 g of active fraction was obtained from fractions No. 46 to No. 129. This was dissolved in 250 ml of purified water, adjusted to pH 7.0 and adsorbed on a column charged with 330 ml of an ion exchange resin (Diaion PK-208(H+), Mitsubishi Chemical Corporation). Chromatography was performed using a concentration gradient formed with 700 ml of purified water and 700 ml of 0.5 N aqueous ammonia to collect 5 ml fractions. Fractions No.169 to No.240 were collected to afford 5.5 g of active fraction.
- Then, 2 g of the above active fraction was dissolved in 50 ml of purified water, subjected to column chromatography using a column charged with 830 ml of a molecular sieving resin (Sephadex G-10, Pharmacia) and purified water at pH 7.9 and fractionated into 3 ml fractions. Fractions No. 49 to No. 53 were collected to afford 124 mg of an active fraction. Similarly, 1.0 g out of 5.5 g of the above active fraction was dissolved in 20 ml of purified water, subjected to column chromatography using a column charged with 470 ml of a molecular sieving resin (Sephadex G-10, Pharmacia) and purified water at pH 7.9 and fractionated into 2 ml fractions. Fractions No. 19 to No. 30 were collected to afford 145 mg of an active fraction. This 145 mg of active fraction was combined with the previously obtained 124 mg of active fraction dissolved in 10 ml of purified water, adjusted to pH 7.3, subjected to column chromatography using a column charged with 480 ml of a molecular sieving resin (Sephadex G-10, Pharmacia) and purified water and fractionated into 2 ml fractions. Fractions No. 49 to No. 55 were collected to afford 84 mg of an active fraction.
- This 84 mg of active fraction was dissolved in 5 ml of purified water, adjusted to pH 7.25, subjected to column chromatography using a column charged with 340 ml of a molecular sieving resin (TOYOPEARL HW-40S, Tosoh) and purified water and fractionated into 2 ml fractions. Fractions No. 38 to No. 52 were collected and lyophilized to afford 7.2 mg of the MK7634 substance as colorless powder.
- Similarly, 2.5 g out of the above 5.5 g of the active fraction afforded by the chromatography utilizing the above ion exchange resin (Diaion PK-208(H+), Mitsubishi Chemical Corporation) was dissolved in 60 ml of purified water, subjected to column chromatography using a column charged with 830 ml of a molecular sieving resin (Sephadex G-10, Pharmacia) and purified water at pH 7.4 and fractionated into 3 ml fractions. Fractions No. 24 to No. 36 were collected to afford 203 mg of an active fraction. This 203 mg of active fraction was dissolved in 10 ml of purified water, adjusted to pH 7.3, subjected to column chromatography using a column charged with 600 ml of a molecular sieving resin (Sephadex G-10, Pharmacia) and purified water and fractionated into 2 ml fractions. Fractions No. 37 to No. 47 were collected to afford 74.7 mg of an active fraction. This 74.7 mg of active fraction was dissolved in 6 ml of purified water, adjusted to pH 7.3, subjected to column chromatography using a column charged with 340 ml of a molecular sieving resin (TOYOPEARL HW-40S, Tosoh) and purified water and fractionated into 2 ml fractions. Fractions No. 56 to No. 67 were collected and lyophilized to afford 4.0 mg of the MK7634 substance as colorless powder.
- Physicochemical characteristics of the MK7634 substance corresponded to those described above. The molecular weight and the molecular formula were obtained by determining high resolution mass spectrum of a monodansylated compound of the substance, which was obtained by dansylating the substance. Values of chemical sift and association constant according to 1H-NMR (Fig. 3) and values of chemical sift according to 13C-NMR (Fig. 4) of the MK7634 substance in a mixed solvent of deuterium oxide and deuterated methanol (weight mixing ratio =4:1) are shown below.
- 1H-NMR δ(ppm);
- 8.63 d(1H, J=8Hz), 8.45 d(1H, J=8Hz), 8.33 d(1H, J=8Hz), 7.75 m(2H) 7.46 d(1H, J=8Hz), 4.26 m(3H) 3.80 t(1H, J=3Hz), 2.90 s(6H), 2.28 m(2H), 1.97 m(1H), 1.56 m(1H)
- 13C-NMR δ(ppm);
- 175.7, 175.1, 151.7, 133.0, 132.7, 131.6, 130.3, 130.2, 129.9, 125.1, 120.1, 117.3, 70.5, 64.5, 59.6, 54.5, 45.9, 33.0, 21.5
- A chicken artificially infected with chicken roundworms, whose chicken roundworm infection had been confirmed by fecal smear examination, was used as one group for each of four density grades. Five chickens in total including one no medication group were examined. The MK7634 substance was orally administered at one time by a feeding tube as a gelatin capsule containing a dose accurately calculated based on body weight of each chicken. After administration, number of discharged roundworms was counted for each chicken every day and, 7 days later, each chicken was dissected to count the residual number of the worm in the bowel and calculate the worm discharging ratio.
-
- The results of the above examination are shown in Table 2. The MK7634 substance showed a worm discharging ratio of 97.4 % at 6.06 mg/kg. The body weight increasing ratio was almost equal to that of no medication control even when this substance was administered at 31.9 mg/kg and hence it was confirmed that the MK7634 substance was a relatively safe drug.
Table 2 Chicken roundworm discharging test by MK7634 substance administration Chicken No. Administration dose (mg/kg) Worm discharging ratio (%) Body weigh increasing ratio (%) 1 No medication 0 18.0 2 2.89 61.3 49.3 3 6.06 97.4 16.4 4 15.3 100 23.4 5 31.9 100 25.0 - The MK7634 substance of the present invention is expected to be used as an anthelmintic against parasites in humans and/or domestic animals and fowls and the like.
Claims (5)
- MK7634 substance which is basic and water-soluble and has the following physicochemical properties:(1) Color and form: colorless powder(2) Molecular formula: C8H15N3O4(3) Specific rotation: [α]D25= +32.8° (c = 0.5, H2O)(4) Mass spectrum (SI-MS): m/z 240 (MNa)+, 218 (MH)+(5) Ultra-violet absorption spectrum: λmax (H2O) nm = 193(end absorption)(6) Infra-red absorption spectrum: νmax (KBr)cm-1 = 3400, 1670, 1630, 1405, 1350, 1090, 970(7) Melting point: gradually colored and decomposed from 175°C(8) Solubility: soluble in water and insoluble in ether, chloroform and ethyl acetate(9) basicity, acidity and neutrality: basic(10) Color reaction: positive in ninhydrin, GL and molybdic acid reactions(11) Thin layer chromatography: Rf value is 0.3 (developing solvent is a mixed solvent of n-butanol, ethanol, chloroform and 17% ammonia (weight mixing ratio = 4:5:2:5).
- A process for producing MK7634 substance, which comprises culturing a microorganism belonging to imperfect fungi and capable of producing the MK7634 substance of claim 1 and collecting the MK7634 substance from its culture.
- The process of claim 2, wherein the imperfect fungus is a microorganism belonging to the genus Curvularia.
- A drug comprising the MK7634 substance of claim 1 as an active ingredient.
- The drug of claim 4, which is an anthelmintic.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP290057/94 | 1994-11-24 | ||
JP29005794 | 1994-11-24 | ||
JP29005794 | 1994-11-24 | ||
PCT/JP1995/002387 WO1996016070A1 (en) | 1994-11-24 | 1995-11-22 | Substance mk7634, process for production thereof, and anthelminthic containing said substance |
Publications (3)
Publication Number | Publication Date |
---|---|
EP0794193A1 true EP0794193A1 (en) | 1997-09-10 |
EP0794193A4 EP0794193A4 (en) | 1998-06-10 |
EP0794193B1 EP0794193B1 (en) | 2000-03-22 |
Family
ID=17751235
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP95937171A Expired - Lifetime EP0794193B1 (en) | 1994-11-24 | 1995-11-22 | Substance mk7634, process for production thereof, and anthelminthic containing said substance |
Country Status (13)
Country | Link |
---|---|
US (1) | US6007812A (en) |
EP (1) | EP0794193B1 (en) |
JP (1) | JP3335177B2 (en) |
KR (1) | KR100406516B1 (en) |
CN (1) | CN1067081C (en) |
AT (1) | ATE190980T1 (en) |
AU (1) | AU696583B2 (en) |
DE (1) | DE69515903T2 (en) |
DK (1) | DK0794193T3 (en) |
ES (1) | ES2145932T3 (en) |
NZ (1) | NZ295747A (en) |
PT (1) | PT794193E (en) |
WO (1) | WO1996016070A1 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6150378A (en) | 1997-10-07 | 2000-11-21 | Cephalon, Inc. | Peptidyl-containing α-ketoamide cysteine and serine protease inhibitors |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1992005191A1 (en) * | 1990-09-17 | 1992-04-02 | Novo Nordisk A/S | Fungicidally active compounds |
EP0488224A2 (en) * | 1990-11-28 | 1992-06-03 | Mitsubishi Kasei Corporation | Fermentationproduct of a Verticimonosporium strain and feed additivs containing a linear peptide |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR1434920A (en) * | 1959-07-31 | 1966-04-15 | Upjohn Co | Process for obtaining streptozotocin |
-
1995
- 1995-11-22 NZ NZ295747A patent/NZ295747A/en not_active IP Right Cessation
- 1995-11-22 DK DK95937171T patent/DK0794193T3/en active
- 1995-11-22 US US08/849,301 patent/US6007812A/en not_active Expired - Fee Related
- 1995-11-22 AT AT95937171T patent/ATE190980T1/en not_active IP Right Cessation
- 1995-11-22 PT PT95937171T patent/PT794193E/en unknown
- 1995-11-22 WO PCT/JP1995/002387 patent/WO1996016070A1/en active IP Right Grant
- 1995-11-22 DE DE69515903T patent/DE69515903T2/en not_active Expired - Lifetime
- 1995-11-22 EP EP95937171A patent/EP0794193B1/en not_active Expired - Lifetime
- 1995-11-22 ES ES95937171T patent/ES2145932T3/en not_active Expired - Lifetime
- 1995-11-22 JP JP51673896A patent/JP3335177B2/en not_active Expired - Fee Related
- 1995-11-22 KR KR1019970703435A patent/KR100406516B1/en not_active IP Right Cessation
- 1995-11-22 CN CN95197347A patent/CN1067081C/en not_active Expired - Fee Related
- 1995-11-22 AU AU39357/95A patent/AU696583B2/en not_active Ceased
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1992005191A1 (en) * | 1990-09-17 | 1992-04-02 | Novo Nordisk A/S | Fungicidally active compounds |
EP0488224A2 (en) * | 1990-11-28 | 1992-06-03 | Mitsubishi Kasei Corporation | Fermentationproduct of a Verticimonosporium strain and feed additivs containing a linear peptide |
Non-Patent Citations (1)
Title |
---|
See also references of WO9616070A1 * |
Also Published As
Publication number | Publication date |
---|---|
ATE190980T1 (en) | 2000-04-15 |
JP3335177B2 (en) | 2002-10-15 |
AU696583B2 (en) | 1998-09-17 |
CN1067081C (en) | 2001-06-13 |
AU3935795A (en) | 1996-06-17 |
EP0794193A4 (en) | 1998-06-10 |
DE69515903T2 (en) | 2000-10-26 |
ES2145932T3 (en) | 2000-07-16 |
KR100406516B1 (en) | 2004-06-24 |
US6007812A (en) | 1999-12-28 |
WO1996016070A1 (en) | 1996-05-30 |
NZ295747A (en) | 1998-04-27 |
PT794193E (en) | 2000-08-31 |
DE69515903D1 (en) | 2000-04-27 |
DK0794193T3 (en) | 2000-12-04 |
EP0794193B1 (en) | 2000-03-22 |
CN1173180A (en) | 1998-02-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0382173B1 (en) | PF 1022 substance, method of producing same and anthelmintic composition containing same | |
AU688405B2 (en) | Polycyclic antiparasitic agents, process and strain for their preparation and their use | |
US20070191415A1 (en) | Production of tacrolimus (fk-506) using new streptomyces species | |
CH668974A5 (en) | ANTITUMOR-ANTIBIOTIC. | |
EP0794193B1 (en) | Substance mk7634, process for production thereof, and anthelminthic containing said substance | |
EP0345735A2 (en) | Glycoside antibiotics BU-3608D and BU-3608E | |
CA2205420C (en) | Substance mk7634, process for production thereof, and anthelminthic containing said substance | |
US5854276A (en) | Substance WF16616, process for production thereof, and use thereof | |
EP0525361B1 (en) | Novel antibiotics NK374186A, NK374186B, NK374186B3 and NK374186C3, process for producing the same, and use of the same | |
EP0677513A1 (en) | Octahydro-2-naphthalenecarboxylic acid derivative, its production and use | |
KR0143769B1 (en) | Antimicrobial polypeptide compound, method for producing the same, and pharmaceutical composition containing the same | |
CA2007895A1 (en) | Janthinocin | |
EP0488224A2 (en) | Fermentationproduct of a Verticimonosporium strain and feed additivs containing a linear peptide | |
JPH08131180A (en) | Production of cytochalasin and anticoccidial agent containing the same | |
JPH05331171A (en) | New metabolic product obtained from pseurochin f1/f2 aspergillus fumigatus, preparation thereof and its use | |
JPH05194571A (en) | New antibiotic nk374186a, nk374186b, nk374186b3 and nk374186c3, their production and their use | |
AT388385B (en) | Novel antibiotics, a microbiological process for their preparation and their use as medicaments | |
JP2815166B2 (en) | New antibiotic MK1688 and its production | |
EP0405151A1 (en) | Antibiotic LL-E19085 | |
JPH11106344A (en) | New bioactive substance nf06307, its preparation and use | |
JPS60130394A (en) | Novel antibiotic sf-2324 substance, preparation, and use thereof | |
JPH07258263A (en) | Neuron differentiation promoter and its production | |
WO2001029182A1 (en) | Novel compound, wf217 | |
JP2003026684A (en) | Mb7056a substance and mb7056b substance, method for producing the same and use thereof | |
JPS60218382A (en) | Xanthone derivative |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 19970530 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 19980422 |
|
AK | Designated contracting states |
Kind code of ref document: A4 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE |
|
GRAG | Despatch of communication of intention to grant |
Free format text: ORIGINAL CODE: EPIDOS AGRA |
|
17Q | First examination report despatched |
Effective date: 19990312 |
|
GRAG | Despatch of communication of intention to grant |
Free format text: ORIGINAL CODE: EPIDOS AGRA |
|
GRAG | Despatch of communication of intention to grant |
Free format text: ORIGINAL CODE: EPIDOS AGRA |
|
GRAH | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOS IGRA |
|
GRAH | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOS IGRA |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SE Free format text: THE PATENT HAS BEEN ANNULLED BY A DECISION OF A NATIONAL AUTHORITY Effective date: 20000322 Ref country code: LI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20000322 Ref country code: GR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20000322 Ref country code: CH Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20000322 Ref country code: AT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20000322 |
|
REF | Corresponds to: |
Ref document number: 190980 Country of ref document: AT Date of ref document: 20000415 Kind code of ref document: T |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP |
|
REF | Corresponds to: |
Ref document number: 69515903 Country of ref document: DE Date of ref document: 20000427 |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D |
|
ITF | It: translation for a ep patent filed |
Owner name: JACOBACCI & PERANI S.P.A. |
|
ET | Fr: translation filed | ||
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FG2A Ref document number: 2145932 Country of ref document: ES Kind code of ref document: T3 |
|
REG | Reference to a national code |
Ref country code: PT Ref legal event code: SC4A Free format text: AVAILABILITY OF NATIONAL TRANSLATION Effective date: 20000601 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20001122 Ref country code: IE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20001122 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MC Free format text: THE PATENT HAS BEEN ANNULLED BY A DECISION OF A NATIONAL AUTHORITY Effective date: 20001130 |
|
REG | Reference to a national code |
Ref country code: DK Ref legal event code: T3 |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
26N | No opposition filed | ||
REG | Reference to a national code |
Ref country code: IE Ref legal event code: MM4A |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: IF02 |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: 732E |
|
NLS | Nl: assignments of ep-patents |
Owner name: NIHON NOHYAKU CO., LTD. |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: TQ |
|
REG | Reference to a national code |
Ref country code: ES Ref legal event code: PC2A |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: ES Payment date: 20071219 Year of fee payment: 13 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: IT Payment date: 20071127 Year of fee payment: 13 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: PT Payment date: 20071112 Year of fee payment: 13 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: BE Payment date: 20071130 Year of fee payment: 13 |
|
BERE | Be: lapsed |
Owner name: *MEIJI SEIKA KAISHA LTD Effective date: 20081130 Owner name: *NIHON NOHYAKU CO. LTD Effective date: 20081130 |
|
REG | Reference to a national code |
Ref country code: PT Ref legal event code: MM4A Free format text: LAPSE DUE TO NON-PAYMENT OF FEES Effective date: 20090522 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: PT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20090522 Ref country code: IT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20081122 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: BE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20081130 |
|
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FD2A Effective date: 20081124 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: ES Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20081124 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: NL Payment date: 20101116 Year of fee payment: 16 Ref country code: FR Payment date: 20101123 Year of fee payment: 16 Ref country code: DK Payment date: 20101110 Year of fee payment: 16 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: DE Payment date: 20101117 Year of fee payment: 16 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: GB Payment date: 20101117 Year of fee payment: 16 |
|
REG | Reference to a national code |
Ref country code: NL Ref legal event code: V1 Effective date: 20120601 |
|
REG | Reference to a national code |
Ref country code: DK Ref legal event code: EBP |
|
GBPC | Gb: european patent ceased through non-payment of renewal fee |
Effective date: 20111122 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: NL Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20120601 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: ST Effective date: 20120731 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R119 Ref document number: 69515903 Country of ref document: DE Effective date: 20120601 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: DK Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20111130 Ref country code: GB Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20111122 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: FR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20111130 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: DE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20120601 |